Advanced Adult Hepatocellular Carcinoma
Oncology·MeSH: Carcinoma, Hepatocellular
Prevalence
5.0 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| AZD9150 | ASTRAZENECA PLC (AZN) |
Phase 2(1)
| Drug | Company |
|---|---|
| enmd-2076 | CASI Pharmaceuticals, Inc. (CASIF) |
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Adult Hepatocellular Carcinoma?
BioSniper tracks 2 drugs in development for Advanced Adult Hepatocellular Carcinoma across 2 companies.
How many clinical trials target Advanced Adult Hepatocellular Carcinoma?
There are 2 clinical trials targeting Advanced Adult Hepatocellular Carcinoma tracked by BioSniper.
What is the prevalence of Advanced Adult Hepatocellular Carcinoma?
The estimated prevalence of Advanced Adult Hepatocellular Carcinoma is approximately 5.0 per 100,000 population.
Deep-dive into Advanced Adult Hepatocellular Carcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis